Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update

In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rinnerthaler, Gabriel, Singer, Christian, Petru, Edgar, Egle, Daniel, Petzer, Andreas, Pluschnig, Ursula, Gampenrieder, Simon Peter, Pfeiler, Georg, Gnant, Michael, Grünberger, Birgit, Krippl, Peter, Strasser-Weippl, Kathrin, Suppan, Christoph, Brunner, Christine, Pusch, Renate, Sandholzer, Margit, Balic, Marija, Bartsch, Rupert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2022
Materias:
Consensus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606043/
https://www.ncbi.nlm.nih.gov/pubmed/36149495
http://dx.doi.org/10.1007/s00508-022-02082-3
Descripción
Sumario:In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those patients. For this consensus paper a total of eight scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.

Ejemplares similares